Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Long-term Objective C  

$2,302,240.00
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4LC. Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. IACC Recommended Budget: $10,000,000 over 5 years.

Download 2010 Question 4: Long-term Objective C projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Pharmacotherapy of pervasive developmental disorders Stigler, Kimberly Indiana University-Purdue University Indianapolis
4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD Scahill, Lawrence Yale University
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders McDougle, Christopher Indiana University
1/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McDougle, Christopher Indiana University-Purdue University Indianapolis
Targeted pharmacologic interventions for autism McDougle, Christopher Indiana University-Purdue University Indianapolis
3/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McCracken, James University of California, Los Angeles
2/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD King, Bryan Seattle Children's Hospital

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015.

IACC Recommended Budget: $10,000,000 over 5 years
N/A

4.L.C
$1,061,222
7 projects

4.L.C
$2,302,240
7 projects

4.L.C
$2,834,887
8 projects

4.L.C
$277,072
3 projects

$6,475,421
4.L.C. Funding: The recommended budget was partially met. 

Progress: A small number (3-7) of studies of pharmacological interventions for co-occurring conditions was funded. There exist many studies examining drugs that are in active use for ADHD that are now being adapted to ADHD-ASD patient groups.

Remaining Gaps, Needs, and Opportunities: There currently is much need for greater understanding of drug efficacy in ASD populations.